Tempest Therapeutics Inc
Change company Symbol lookup
Select an option...
TPST Tempest Therapeutics Inc
PETV PetVivo Holdings Inc
KMI Kinder Morgan Inc
NXPL NextPlat Corp
D Dominion Energy Inc
CVS CVS Health Corp
CVI CVR Energy Inc
CTRE CareTrust REIT Inc
CSWC Capital Southwest Corp
CSCO Cisco Systems Inc
Go

Health Care : Biotechnology |
Company profile

Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.

Closing Price
$1.85
Day's Change
-0.20 (-9.76%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.04
Day's Low
1.76
Volume
(Heavy Day)
Volume:
142,808

10-day average volume:
64,949
142,808

ALIZY SHAREHOLDER ALERT: Jakubowitz Law Reminds Allianz Shareholders of a Lead Plaintiff Deadline of April 3, 2023

5:45 am ET March 3, 2023 (PR Newswire) Print

Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Allianz SE (OTC Other: ALIZY).

To receive updates on the lawsuit, fill out the form:https://claimyourloss.com/securities/allianz-class-action-lawsuit-loss-submission-form/?id=36972&from=4

The lawsuit seeks to recover losses for shareholders who purchased Allianz between March 9, 2018 andMay 17, 2022.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until April 3, 2023 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Allianz SE issued materially false and/or misleading statements and/or failed to disclose that: (1) Allianz did not have effective internal controls; (2) Allianz's subsidiary was involved in substantial fraudulent activity; (3) as a result, Allianz was at an increased risk of regulatory scrutiny; (4) as a result, Allianz was at an increased risk of substantial losses and financial costs; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (628) 895-0423F: (212) 537-5887

https://c212.net/c/img/favicon.png?sn=NY31138&sd=2023-03-03

View original content:https://www.prnewswire.com/news-releases/alizy-shareholder-alert-jakubowitz-law-reminds-allianz-shareholders-of-a-lead-plaintiff-deadline-of-april-3-2023-301761700.html

SOURCE Jakubowitz Law

https://rt.newswire.ca/rt.gif?NewsItemId=NY31138&Transmission_Id=202303030545PR_NEWS_USPR_____NY31138&DateId=20230303

comtex tracking

COMTEX_425831021/1005/2023-03-03T05:45:10

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.